Top Stories

General Motors Co. (GM) is recalling nearly 49,000 trucks worldwide to fix a fuel tank issue that can increase the risk of a fire. The recall covers Chevrolet Silverado 3500 and GMC Sierra 3500 trucks from the 2011 through 2015 model years, all equipped...

Merval, the main index of the Buenos Aires Stock Exchange, left an initial technical rebound to fall again (-0.49%) Friday, closing at 27,131.57 points. During the week, the Merval closed stable. Jorge Juarez, an analyst at Mateo and Marchioni Sociedad...


The Chairman of the Joint Chiefs of Staff (CJCS) has warned that the United States' military advantage against near-peer competitors Russia and China is eroding, and it is no longer as decisive as it was some years ago. General Joseph Dunford sounded...


While selling pressure was relatively subdued, stocks saw modest weakness during trading on Friday. The major averages all moved to the downside, with the tech-heavy Nasdaq pulling back off the record closing high set in the previous session.


Shakira has announced that she is postponing her European tour until next year to rest and fully recover from a hemorrhage on her vocal cords. The pop diva is disappointing thousands of her fans days after announcing the cancellation of her El Dorado...

The biennial Dubai Air Show opened Sunday with Emirates placing a preliminary order worth $15 billion for 40 787-10 Dreamliners from Boeing. Emirates Chairman Sheikh Ahmed bin Saeed al-Maktoum said the aircraft had been chosen over the Airbus A350....
Hasbro Inc. (HAS) has reportedly offered to acquire its key rival Mattel Inc. (MAT), a merger deal that could combine the two biggest toy makers in the U.S. According to a report on the WSJ, Hasbro had recently approached Mattel with the deal. However,...
Pharma-111017.jpg Today's Daily Dose brings you news about Arena's progress in phase II study of Etrasimod in ulcerative colitis; expanded FDA approval of Bristol-Myers' leukemia drug Sprycel; voluntarily delisting of Mylan's ordinary shares from the Tel Aviv Stock Exchange and Vanda's disappointment over Fanaptum's failure to win the CHMP's backing.
Asian-Markets1_12Nov17.jpg Asian stock markets are turning in a mixed performance on Monday following the mostly negative cues from Wall Street on Friday amid worries about the fate of proposed U.S. tax reform. Meanwhile, the British pound fell after the Sunday Times reported that 40 Conservative members of Parliament intend to sign a letter of no-confidence in British Prime Minister Theresa May.
AlexAzar-111317.jpg President Donald Trump announced Monday he is nominating former pharmaceutical company executive Alex Azar as secretary of the U.S. Health and Human Services Department. Azar, a prominent Obamacare critic, previously served as president of Lilly USA,...
OrrinHatch-111717.jpg Republican members of the Senate Finance Committee voted Thursday to approve their version of tax reform legislation. The committee voted 14 to 12 in favor of the $1.5 trillion tax reform bill, with the vote coming down strictly along party lines....
Moodys-India-111717.jpgMoody's Investors Service on Friday raised the sovereign ratings of India for the first time since 2004, citing economic and institutional reforms. The sovereign rating was lifted to Baa2 from Baa3 and the rating outlook was changed to 'stable' from 'positive'. The upgrade has placed India's rating at par with those of Italy and the Philippines.
Billionaire and Microsoft co-founder Bill Gates is making a personal investment of $50 million into the Dementia Discovery Fund, a venture capital fund that invests in projects and companies to develop treatments for the brain-wasting disease. The investment is not part of Gates' philanthropic Bill & Melinda Gates Foundation, which has focused primarily on infectious diseases.
The Canadian market was in a better mood Friday as oil prices showed a strong move back to the upside. The TSX Composite Index was up 63 points or 0.4 percent to 15,998,57, trimming this week's losses. The index topped 16,000 for the first time ever earlier this month. Energy stocks added 0.4 percent....
Apparel retailer Abercrombie & Fitch Co. on Friday reported a 28 percent increase in profit for the third quarter from last year on higher sales. Both revenue and adjusted earnings per share for the quarter beat analysts' estimates. The company's shares are gaining more than 20 percent in pre-market activity.
Today's Daily Dose brings you news about Aerie's progress in phase II trial of glaucoma drug in Japan; phase III results of Egalet's pain pill; FDA approval of GlaxoSmithKline's COPD drug; expanded labeling for Pfizer's kidney cancer drug Sutent and Roche's double blessing on Thursday. More
Shares of Catalyst Pharmaceuticals Inc. (CPRX) are up an impressive 179% year-to-date while the iShares NASDAQ Biotechnology Index ETF (IBB) has gained just 17% during the same period. More
HealthIQ-111517.jpg Health IQ Insurance Services, a startup focused on providing life insurance for health-conscious individuals, said it has secured $34.6 million in Series C funding, led by Andreessen Horowitz. To date, the company has raised a total of $81 million in funding mostly from its existing investors.
Follow RTT
Economic Calendar
11/19/17 GDP (Q-o-Q)Q3 Thailand
11/19/17 GDP (Y-o-Y)Q3 Thailand
11/17/17 13:0Baker Hughes - Rig CountNOV 17 United States
11/17/17 10:30CB Coincidence IndexSEP Australia
11/17/17 10:30CB Leading IndexSEP Australia
11/17/17 9:30CB Coincidence IndexSEP France
Complete Economic Calendar
FDA Calendar
Event DateSymbolDrug NameEvent Name
02/14/18AMAG, AMAGMakena subcutaneous auto-injector (sNDA)FDA decision on subcutaneous version of Makena to reduce the risk of preterm birth
01/24/18SGYPTRULANCE (sNDA)FDA decision on TRULANCE for the treatment of adults with irritable bowel syndrome with constipation
01/12/18LGNDLUXTURNA (BLA)FDA decision on LUXTURNA for inherited retinal disease
01/12/18ONCELUXTURNA (BLA)FDA decision on LUXTURNA for treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy.
01/10/18LLYAbemaciclib (NDA)FDA decision on Abemaciclib for the treatment of advanced breast cancer
Complete FDA Calendar